Abstract
Background
Dysbacteriosis is thought to play an important role in the pathogenesis of necrotizing enterocolitis (NEC). We aimed to identify new biomarkers among gut microbiota and short-chain fatty acids (SCFAs) for the early prediction of NEC.
Materials and methods
Thirty-four preterm infants with gestational ages of ≤ 34 weeks who developed gastrointestinal symptoms were divided into the NEC group (n = 17) and non-NEC group (n = 17). In the NEC group, the gut microbiota and SCFAs in feces were assessed when the infants were enrolled (Group P) and when they were diagnosed with NEC (Group N). In the non-NEC group, samples were assessed when the infants were enrolled (Group C).
Results
The Ace and Chao1 indices were higher in Group P than in Group C (P < 0.05), and there was no difference between Groups C and N or between Groups P and N (P > 0.05). There was no significant difference in the Simpson and Shannon indices among Groups C, P and N (P > 0.05). The four main phyla showed no differences (P > 0.05) in composition, while at the genus level, compared with Group C, in Group P, Clostridioides, Blautia and Clostridium_sensu_stricto_1 were increased, while Lactobacillus and Bifidobacterium were decreased (P < 0.05). At the species level, Streptococcus salivarius and Rothia mucilaginosa increased, while Bifidobacterium animals subsp. lactis decreased (P < 0.05). In Group N, at the genus level, Stenotrophomonas, Streptococcus and Prevotella increased (P < 0.05). Compared with those in Group C, the levels of acetic acid, propanoic acid and butyric acid decreased significantly in Groups P and N (P < 0.05), and the areas under the curves (AUCs) of these three SCFAs between groups C and P were 0.73, 0.70, and 0.68, respectively.
Conclusion
The increase in Streptococcus salivarius and Rothia mucilaginosa and decrease in Bifidobacterium_animals_subsp._lactis, as well as the decrease in acetic, propionic and butyric acids, may help in the early prediction of NEC.
Keywords: neonatal necrotizing enterocolitis, gut microbiota, short-chain fatty acids, metabolites, predict
Introduction
Neonatal necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal diseases during the neonatal period (Neu and Walker, 2011). In preterm infants, the incidence is 5–12% and up to 13% in those born with very low birth weight. Despite improvements in the management of neonates, the fatality rate is still as high as 20% to 30% and is even higher in those requiring surgery (Foglia et al., 2019; Meister et al., 2020). Severe neurological retardation, enterostenosis after surgery, short bowel syndrome, cholestasis and other complications can subsequently affect the quality of life of infants (Frost et al., 2017; Allendorf et al., 2018). Therefore, there is an urgent need to identify NEC early and intervene as soon as possible.
The diagnosis of NEC depends mainly on clinical features and imaging findings. However, it is always ignored in the early stage, and once the typical features appear, it progresses rapidly in most patients (Neu and Walker, 2011; Meister et al., 2020). Therefore, some biomarkers, such as levels of fecal calprotectin, high mobility group box-1 protein, and intestinal-fatty acid binding protein, have been used to diagnose NEC early (Arboleya et al., 2015; Willers et al., 2020; Huo et al., 2021). However, most of these biomarkers are released due to epithelial cell damage in the intestine with low detection sensitivity in the early stage (Goldstein and Sylvester, 2019).
Epidemiological findings and animal models suggest that dysbacteriosis is one of the risk factors for NEC and plays an important role in the pathogenesis of NEC (Waligora-Dupriet et al., 2005; Schnabl et al., 2008). Previous studies have shown that decreased microbial diversity is one of the features of infants with NEC (Lynch and Pedersen, 2016; Niño et al., 2016; Dobbler et al., 2017; Lee et al., 2020) and that the abundance of Proteobacteria is increased while those of Firmicutes and Bacteroidota are decreased significantly in infants with NEC (Pammi et al., 2017). These symptoms occur 72 h to 7 days before the onset of NEC, so these microbiotas have early predictive value for NEC to some extent (Mai et al., 2011; Tarracchini et al., 2021). In addition, studies have shown that the metabolites of microbiota also play an important role in the disease process and have been regarded as a bridge between microbiota and diseases, including NEC(Macia et al., 2015; Zhu et al., 2016). Therefore, the relationship between microbiota metabolites and NEC has received more attention in recent years (Call et al., 2018; Neu and Pammi, 2018).
Many metabolites, including bile acids, short-chain fatty acids (SCFAs), branched-chain amino acids, trimethylamine N-oxide, tryptophan and indole derivatives, have been reported to be important in physiological functions (McCarville et al., 2020; Agus et al., 2021). Among these metabolites, SCFAs have become a focal point in recent years. SCFAs are organic fatty acids that contain 1–6 carbon atoms and include formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid(Koh et al., 2016). Studies have shown that SCFAs play an important role in maintaining the integrity of the intestinal epithelium and repairing the mucosa after injury (Gonçalves et al., 2018; Kayama et al., 2020). For example, propionic acids increase the expression levels of the tight junction proteins zonula occludens-1 and occludin on the epithelial barrier in patients with Parkinson’s disease (Huang et al., 2021), and valeric acid can reduce the incidence of necrotic enteritis in chickens (Onrust et al., 2018). However, few studies have focused on the role of SCFAs in the pathogenesis of NEC, and it remains unclear whether SCFAs are valuable for predicting NEC.
The aim of this study was to explore the value of the gut microbiota and SCFAs in predicting NEC and find new potential biomarkers for the early diagnosis of NEC.
Subjects and methods
A prospective study enrolling neonates admitted to the Neonatal Diagnosis and Treatment Center of Children’s Hospital of Chongqing Medical University from April to October 2021 was conducted. This study was approved by the Ethics Committee of the Children’s Hospital Affiliated with Chongqing Medical University (No. 2021-32-1) and registered in the China Clinical Trial Center (ChiCTR2100044736). Informed consent forms were obtained from the parents of the enrolled neonates.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) infants with a gestational age less than 34 weeks and (2) infants presenting with one of the following symptoms, namely, abdominal distension, vomiting or bloody stool. The exclusion criteria were as follows: (1) infants who died during hospitalization or were diagnosed with congenital gastrointestinal malformations such as congenital intestinal atresia, megacolon, intestinal malrotation or other gastrointestinal diseases such as food-protein-induced enteritis or lactose intolerance; (2) infants for whom fecal samples were not collected at enrollment or for whom the microbiota and SCFAs were not completely assessed; and (3) infants with a lack of consent to participate in this study.
Diagnostic criteria
NEC was diagnosed based on Bell’s diagnostic criteria (Kliegman and Walsh, 1987). Infants who met the following criteria were enrolled in the NEC group: (1) one or more of the systemic symptoms, including drowsiness, an unstable body temperature, apnea, and bradycardia and/or (2) had one or more of the clinical signs, including gastric aspirate with bile or emesis, abdominal distention, and occult and/or gross bloody stool, and (3) had at least one of the imaging findings, including pneumatosis intestinalis, portal vein gas and/or pneumoperitoneum. The non-NEC infants enrolled at the same time were matched 1:1 according to gestational age and birth weight. The gestational age difference was less than 1 week, and the birth weight difference was less than 250 grams. Feeding intolerance (FI) in the non-NEC group was diagnosed based on the following criteria: (1) gastric retention exceeding 50% of the previous feeding volume; (2) the presence of emesis, abdominal distention or both; and (3) a failed enteral feeding plan including a decrease, detention, or discontinuity.
Data collection
Relevant clinical data of the enrolled infants were collected, including baseline information, risk factors for prenatal (maternal, gestational and intrapartum) and pre-enrollment (feeding, antibiotic use, invasive procedures, etc.) conditions, and hospitalization outcomes (duration, surgery and other complications).
Faecal sampling and grouping progress
Naturally-excreted fecal samples were collected with disposable sterile swabs. For infants who ultimately developed NEC, fecal samples were collected at two different time-points to identify the changes in the microbiota and SCFAs with the development of disease. The two time-points were when the infants were enrolled (Group P) and when they were prospectively diagnosed with NEC (Group N). For infants who did not develop NEC, samples were only collected when they were enrolled (Group C) (Figure 1). Fresh samples were immediately transferred to the laboratory, and every 250 mg was aliquoted into 1.5-ml sterile enzymatic EP tubes, which were then stored in a freezer at −80°C.
Microbiota determination
Genomic DNA of the fecal microbiota was extracted with a QIAamp FAST DNA Stool Mini-Kit (Qiagen, Hilden Germany) as previously described (Liu et al., 2022). DNA extracts were tested on a 1% agarose gel, and the concentration and purity were assessed with a spectrophotometer (NanoDrop 2000 UV–vis, Thermo Scientific, Waltham, MA, USA). The V3-V4 hypervariable region of the 16S rDNA genes was amplified with primers 338F (5′-ACTCCTACGGG AGGCAGCAG-3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′). The cycles were as follows: (1) initial denaturation at 95°C for 3 min; (2) denaturation at 95°C for 30 seconds; (3) annealing at 55°C for 30 seconds; and (4) extension at 72°C for 45 seconds. After 27 cycles, an extension at 72°C for 10 min was performed. The products were extracted and recovered by 2% agarose gel electrophoresis (Axygen Biosciences, United States) and then quantified using a Quantus Fluorometer (Promega, United States). Finally, amplicons were pooled in equimolar amounts and subjected to paired-end sequencing (2 × 250) on the Illumina MiSeq platform (San Diego, CA, United States) following standard protocols. Reads were differentiated based on primers and barcodes, and sequence orientation was adjusted to ensure accurate barcode matching.
Raw microbiota data were processed with QIIME (version 1.9.1; Boulder, CO, United States). Briefly, bases with a quality score less than 20 were truncated, and sequences longer than 10 bp overlapped. Reads in overlapping regions of the spliced sequences that exceeded the maximum mismatch ratio of 0.2 were deleted. Sequences were ultimately divided into operational taxonomic units (OTUs) using UPARSE (version 7.0.1090; La Jolla, CA, United States), and OTUs were clustered with a similarity threshold of 97% (Amato et al., 2013). Species classification was performed using silva138/16s_bacteria taxonomic data with a classification confidence of 70%.
Short-chain fatty acids (SCFAs) measurement
The methods have been previously described (Liu et al., 2022). Standards for acetic, propionic, butyric, isobutyric, valeric, isovaleric, and hexanoic acids were prepared with ethyl acetate and 4-methylvaleric acid to standard concentration gradients of 0.1 μg/mL, 0.5 μg/mL, 1 μg/mL, 5 μg/mL, 10 μg/mL, 20 μg/mL, 50 μg/mL and 100 μg/mL. Thirty milligrams of each fecal sample was thawed, and 900 μL of 0.5% phosphoric acid was added to resuspend the sample, which was then shaken for 2 min and centrifuged at 14,000 × g for 10 min. Then, 800 μL of the supernatant was added to an equal amount of ethyl acetate to repeat the above processes, and 600 μL of the upper organic phase was added to 4-methylvaleric acid as an internal standard. The samples were separated by a DB-WAX capillary column (30 m × 0.25 mm ID × 0.25 μm) and analyzed by 7890A/5975C gas chromatography–mass spectrometry (Agilent, Santa Clara, CA, United States). Finally, MSD ChemStation software (Agilent, Santa Clara, CA, United States) was used to extract chromatographic peak areas and retention times. Standard curves were drawn, and the SCFAs content was calculated.
Data analysis
All the clinical data, alpha diversity index values and SCFAs contents were analyzed with SPSS statistical software (version 24; Chicago, IL, United States). Normally distributed data are presented as the mean ± standard deviation (SD) and were compared with matched samples t tests between two groups. Non-normally distributed measurement data are presented as medians (interquartile ranges, IQRs), and the Wilcoxon signed rank-sum test was used. The comparison of SCFAs at different time-points in one infant was performed with a generalized linear mixed model. Count data were analyzed by Fisher’s exact test. The comparisons of the gut microbiota composition were performed with the Kruskal–Wallis H test. Principal coordinate analysis (PCoA) based on the Euclidean distance matrix of the beta diversity and other statistics was performed with R language (version 3.3.1; Auckland, New Zealand). Correlation heatmap analysis was conducted to show the relationship between SCFAs concentrations and the microbiota composition based on Spearman rank correlation in R. Receiver operating characteristic (ROC) curve analysis was performed with GraphPad Prism (version 9.0; La Jolla, CA, United States). P < 0.05 was regarded as statistically significant. Figures illustrating the microbiota results were drafted with R language or GraphPad Prism.
Results
Clinical information
One hundred thirteen preterm infants admitted to our department were enrolled, and 46 infants were suspected to have NEC at the time of enrollment. Among them, 29 infants were excluded from further study due to obvious or suspected gastrointestinal malformations (n = 13), the failure to collect fecal samples at the time of enrollment (n = 13) and incomplete determination of the microbiota and SCFAs (n = 3). Therefore, 17 infants with NEC were enrolled, and 5 developed intestinal perforation on the day of enrollment (Figure 1). Compared with the non-NEC group, the NEC group had a larger corrected gestational age at the time of enrollment. Those with NEC had a higher incidence of septicemia and longer hospitalization stays (P < 0.05). There were no significant differences in other factors, including general information, prenatal risk factors and other risk factors, before enrollment (P > 0.05) (Table 1).
TABLE 1.
Non-NEC (n = 17) | NEC (n = 17) | X 2/Z/t | P | |
General information | ||||
Male, % (n) | 52.9 (9) | 76.5 (13) | / | 0.141 |
Admission age, M (IQR), h | 0.08 (0.04,2.54) | 0.08 (0.06,3.38) | −0.489 | 0.624 |
Gestational age, ± S. D, w | 30.48 ± 1.943 | 30.50 ± 2.120 | −0.081 | 0.936 |
Birth weight, ± S. D, g | 1442.35 ± 346.433 | 1427.35 ± 459.763 | 0.183 | 0.857 |
Cesarean section, % (n) | 41.2 (7) | 35.3 (6) | / | 0.500 |
Apgar 1 min, M (IQR) | 8.00 (6.00,9.00) | 8.00 (7.00,9.00) | −0.996 | 0.319 |
Apgar 5 min, M (IQR) | 9.00 (8.50,10.00) | 9.00 (9.00,9.50) | −0.965 | 0.334 |
Prenatal risk factors | ||||
PROM, % (n) | 23.5 (4) | 29.4 (5) | / | 0.500 |
Intrauterine distress, % (n) | 11.8 (2) | 5.9 (1) | / | 0.500 |
Maternal hypertension, % (n) | 11.8 (2) | 5.9 (1) | / | 0.500 |
GDM, % (n) | 11.8 (2) | 23.5 (4) | / | 0.328 |
Chorioamnionitis, % (n) | 11.8 (2) | 5.9 (1) | / | 0.500 |
Antenatal steroid use, % (n) | 82.4 (14) | 64.7 (11) | / | 0.219 |
Antenatal antibiotic use, % (n) | 23.5 (4) | 0.0 (0) | / | 0.051 |
Risk factors before enrollment | ||||
Formula milk feeding, % (n) | 70.6 (12) | 58.8 (10) | / | 0.360 |
Antibiotic course, M (IQR), d | 5.00 (2.50,7.50) | 4.00 (3.00,10.00) | −0.259 | 0.796 |
Endotracheal intubation, % (n) | 5.9 (1) | 5.9 (1) | / | 0.758 |
PICC period, ± S. D, d | 12.00 ± 11.040 | 19.18 ± 18.762 | −1.737 | 0.102 |
PN courses, ± S. D, d | 13.18 ± 11.690 | 18.29 ± 15.206 | −1.384 | 0.186 |
Transfusion, % (n) | 17.6 (3) | 35.3 (6) | / | 0.219 |
CGA when enrolling, ± S. D, w | 32.52 ± 1.794 | 33.99 ± 2.385 | −3.763 | 0.002 |
Onset age of NEC, ± S. D, d | / | 30.24 ± 15.888 | / | / |
Days from enrollment to the onset of NEC, ± S. D, d | / | 7.00 ± 7.640 | / | / |
Outcome | ||||
Surgery, % (n) | 0.0 (0) | 23.5 (5) | / | 0.051 |
Septicemia, % (n) | 23.5 (4) | 88.2 (15) | / | 0.000 |
IVH, % (n) | 17.6 (3) | 23.5 (4) | / | 0.500 |
BPD,% (n) | 47.1 (8) | 41.2 (7) | / | 0.500 |
Shock, % (n) | 5.9 (1) | 23.5 (4) | / | 0.168 |
Hospital stays, ± S. D, d | 48.41 ± 26.003 | 83.35 ± 47.911 | −3.111 | 0.007 |
NEC, necrotizing enterocolitis; PROM, premature rupture of membranes > 18 h; GDM, Gestational diabetes mellitus; PICC, peripherally inserted central catheter; PN, Parenteral nutrition; CGA, Corrected gestational age; IVH, Intraventricular hemorrhage; BPD, Bronchopulmonary dysplasia.
Microbiota characteristics
Determination and analysis of the microbiota were performed for 46 samples, with 17 from Group P and 5 from infants diagnosed on the enrollment day with intestinal perfusion; only 12 samples were assessed for Group N. According to the pairing principle, 17 samples in Group C were obtained (Figure 1). Core analysis was performed to verify whether the sample size was sufficient, and the curve eventually flattened, which means that the sample size was reasonable (Supplementary Figure 1A). Analysis of similarities (ANOSIM) based on the Bray–Curtis distance algorithm showed that the difference among the three groups was not significantly greater than that within the groups, indicating that the grouping was comparable (Supplementary Figure 1B). A rarefaction curve was drawn based on the Shannon diversity index, and the flat curves showed that the number of sequences measured was sufficient to reflect the vast majority of microbial diversity information (Supplementary Figure 1C).
Diversity analysis
Alpha diversity was assessed based on the Ace and Chao1 richness indices and the Simpson and Shannon diversity indices. The Ace and Chao1 indices in Group C were higher than those in Group P (P < 0.05), and the Simpson and Shannon indices showed no difference (P > 0.05). Groups C and N showed no differences in the four indices. In addition, there were no differences between Groups P and N (P > 0.05) (Figures 2A–D).
PCoA showed that the samples in Groups C, P and N were all relatively discrete, and the explanatory values on the X and Y axes were 19.33% and 17.05%, respectively. ANOSIM showed that there was no significant difference in the beta diversity among the three groups (P > 0.05) (Figure 2E).
Composition of microbiota
The number of OTUs in the three groups and the shared relationship are shown in Venn diagrams. At the phylum level, Proteobacteria, Firmicutes, Actinobacteriota and Bacteroidota were the dominant phyla, and on the ternary phase diagram, the phyla with a total amount of less than 1% were combined, which means that the four main phyla accounted for more than 99% of the total composition. At the genus level, the similarities and differences among the three groups are shown in the heatmap, and different colors show the abundance of different genera. Enterococcus, Escherichia-Shigella, Staphylococcus, Enterobacter, Klebsiella, and Acinetobacter were the main genera, and their relationships with the phyla are presented in the phylogenetic tree (Supplementary Figure 2).
When compared with Group C, in Group P, Proteobacteria increased while Firmicutes, Actinobacteriota and Bacteroidota decreased at the phylum level, but no differences were observed (P > 0.05). Clostridioides, Blautia and Clostridium_sensu_stricto_1 increased, while unclassified_c_Bacilli, Lactobacillus and Bifidobacterium decreased significantly at the genus level (P < 0.05). At the species level, unclassified_g_Clostridioides, Streptococcus salivarius and Rothia mucilaginosa increased, while unclassified_c_Bacilli, unclassified_g_Lactobacillus and Bifidobacterium animals subsp. lactis decreased (P < 0.05) (Figures 3A–C).
When Groups C and N were compared, in Group N, only Firmicutes decreased, while the other three main phyla increased at the phylum level without significant differences (P > 0.05). Stenotrophomonas, Streptococcus and Prevotella increased at the genus level. At the species level, unclassified_g_Stenotrophomonas and unclassified_g_Streptococcus increased (P < 0.05) (Figures 3D–F).
When Groups P and N were compared, in Group N, Proteobacteria and Firmicutes decreased, while Actinobacteriota and Bacteroidota increased without a significant difference (P > 0.05). At the genus level, Faecalibacterium, Microbacterium and Solobacterium increased, and at the species level, metagenome_g_Prevotella, unclassified_g_Faecalibacterium, unclassified_g_Microbacterium, uncultured_bacterium_g_ Solobacterium and Bacteroides_vulgatus increased, while Candidatus_Planktophila_versatilis decreased (P < 0.05). However, these genera and species accounted for a very small proportion of the total (Figure 3G–I).
Short-chain fatty acids (SCFAs) measurement
Acetic, propanoic, butyric and isovaleric acids decreased significantly in Group P compared with Group C, and acetic, propanoic, butyric and isobutyric acids decreased in Group N compared with Group C. Additionally, the total amount of SCFAs in Groups P and N was lower than that in Group C (P < 0.05). Between Groups P and N, there were no differences in any of the SCFAs (P > 0.05) (Figure 4). To determine the value of SCFAs in predicting NEC, ROC curves of acetic, propanoic and butyric acids between Groups C and P were generated, and the AUCs were 0.73, 0.70, and 0.68, respectively (Figure 5).
Relationship between short-chain fatty acids (SCFAs) and the gut microbiota
The relationship between SCFAs and the gut microbiota is shown in the heatmap. At the phylum level, acetic, propanoic, butyric and isobutyric acids were negatively correlated with Bacteroidota, and propanoic acid was positively correlated with Firmicutes (P < 0.05). All SCFAs were positively correlated with Proteobacteria; however, there was no statistically significant difference (P > 0.05) (Figure 6A). At the genus level, propanoic, butyric and isobutyric acids were positively correlated with Halomonas, and most SCFAs were negatively correlated with Lactobacillus, Bacteroides, and Stenotrophomonas (P < 0.05) (Figure 6B).
Discussion
New biomarkers for the early prediction of the onset of NEC are important. In this study, we found that Streptococcus salivarius and Rothia mucilaginosa increased and Bifidobacterium subsp. lactis decreased 7 days before NEC occurred and that acetic, propionic and butyric acid decreased, which showed great value for the early prediction of NEC.
In our study, Proteobacteria increased, while Firmicutes, Actinobacteriota and Bacteroidota decreased at the phylum level, although without significance, and at the genus level, Clostridioides, Blautia and Clostridium_sensu_stricto_1 increased, while unclassified_c_Bacilli, Lactobacillus and Bifidobacterium increased in infants with NEC. Consistent with our study, Clostridium and Bacillus have been previously considered as biomarkers for predicting NEC (de la Cochetiere et al., 2004; Olm et al., 2019; Brehin et al., 2020). However, no studies have clearly proposed which bacteria are closely related to NEC. Therefore, we further analyzed the relevant microbiota at the species level and found that Streptococcus salivarius and Rothia mucilaginosa increased and Bifidobacterium subsp. lactis decreased in the early stage of NEC. In addition, although we found that bacterial species can help to predict NEC, the prediction is limited by the detection methods; some bacteria are identified as unclassified or uncultured species, and some anaerobic bacteria cannot be easily detected clinically.
Our study found that SCFAs may be better biomarkers that can reflect the overall characteristics of the microbiota and can be determined more easily. We found that acetic, propionic and butyric acid levels decreased significantly, and that ROC curve analysis showed predictive values before the diagnosis of NEC. Combined with the heatmap, the production of metabolites was related to the decline in Firmicutes and Bacteroidota, although there was no difference in their abundance at the phylum level. It might be the joint work of the gut microbiota to produce metabolites.
Acetic, propionic and butyric acids are the main SCFAs, which account for approximately 90-95% of the total SCFAs in the human intestines (Soldavini and Kaunitz, 2013) and are mainly produced by the fermentation of dietary fiber by microbiota (McNabney and Henagan, 2017; Ghonimy et al., 2018). The production of acetic acids is distributed across different genera, such as Bacteroides, Bifidobacterium, Lactobacillus and Prevotella, which ferment pyruvate in the acetyl-CoA or Wood-Ljungdahl pathway. Propionic acid is mainly produced from succinate by Bacteroides and Veillonella via the succinate pathway or from lactate by Propionibacterium via the acrylate pathway or propylene glycol pathway. Butyric acid is mainly produced by Clostridium, Lactobacillus, and Clostridium perfringens from acetyl-CoA and butyryl-CoA via the typical pathway or from lactate and acetate via the lactate pathway (den Besten et al., 2013). Previous studies have shown that SCFAs play important roles in intestinal inflammation and are involved in intestinal injury. Li et al. found that a certain concentration of acetic acid alleviated high-carbohydrate-induced intestinal inflammation by inhibiting MAPK activation and NF-κB phosphorylation (Li et al., 2020). Pace et al. showed that propionic and butyric acids can inhibit the intestinal inflammatory response in a human model by reducing the expression of the proinflammatory cytokines Mcp-1 and IL-8 and the gene transcription of chemotactic cytokine family members (Pace et al., 2021). Our previous study found that butyrate intervention attenuated intestinal inflammation and partially corrected dysbacteriosis in mice with NEC (Sun et al., 2021). Thus, the changes in acetic, propionic and butyric acids in our study can reflect the gut conditions caused by NEC and may be helpful for early prediction. In addition, the detection method is simple, and the detection duration is greatly shortened compared with that for detecting the gut microbiota, which makes it easier to be applied clinically.
Walker and Claud first proposed the hypothesis that decreased diversity may lead to NEC in 2001 (Claud and Walker, 2001), which was confirmed by previous studies. However, in our study, the richness of the gut microbiota in the NEC group before the onset of NEC was higher than that in the control group, and the diversity indices and beta diversity showed no differences among the three groups. The larger corrected gestational age in infants with NEC might be the cause of increased richness, which has a strong influence on the development of the gut microbiota during the neonatal period, especially in preterm infants (La Rosa et al., 2014). The infants enrolled in our study were those who presented with gastrointestinal symptoms, and those in Group C were mostly diagnosed with FI. FI can lead to a decrease in diversity and changes in beta diversity, and studies have shown a pattern similar to NEC in patients who developed FI (La Rosa et al., 2014; Li et al., 2021; Liu et al., 2022), which can explain why the diversity showed no differences in our study.
There were some limitations to our study. Our prospective study enrolled infants with gastrointestinal symptoms, but the difference in the time to disease development was ignored, which may affect the microbiota. Second, for the small sample size, the diversity of the microbiota showed no difference, and the predictive value of SCFAs was low in the ROC curve analysis. Further studies with larger samples are needed to make our conclusion more convincing.
Conclusion
Streptococcus salivarius and Rothia mucilaginosa increased, Bifidobacterium_animals_subsp._lactis decreased and acetic, propionic and butyric acids decreased before the diagnosis of NEC, which may help in the early prediction of NEC.
Data availability statement
The datasets for this study can be found in the NCBI (BioProject ID: PRJNA832593 http://www.ncbi.nlm.nih.gov/bioproject/832593) and obtained from the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by Ethics Committee of the Children’s Hospital Affiliated with Chongqing Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.
Author contributions
All the authors made substantial contributions to the study and manuscript and meet the criteria for authorship defined in the author instructions. X-CL and T-TD collected the clinical data and worked on basic sample processing and the drafting of the manuscript. X-CL, T-TD, XG, and W-JZ collected the fecal samples. Z-LW, YH, and L-QL supervised the project and contributed to the conception and design of the study and analysis and interpretation of the data. L-QL contributed to the critical revision and final approval of the manuscript. X-QL, T-TD, and L-QL performed the final approval of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the Natural Science Foundation of Chongqing municipality (cstc2021jcyj-msxmX0063), Joint Medical Research Project of Chongqing Science and Technology Commission (2022MSXM039), China Postdoctoral Science Foundation (No.2022MD713716), the General Basic Research Project from the Ministry of Education Key Laboratory of Child Development and Disorders (No. GBRP-202107), Science and Health Project of Chongqing Health Commission (2020FYYX217), and National Natural Science Foundation of China (82001602).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.969656/full#supplementary-material
References
- Agus A., Clément K., Sokol H. (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70 1174–1182. 10.1136/gutjnl-2020-323071 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Allendorf A., Dewitz R., Weber J., Bakthiar S., Schloesser R., Rolle U. (2018). Necrotizing enterocolitis as a prognostic factor for the neurodevelopmental outcome of preterm infants - match control study after 2years. J. Pediatr. Surg. 53 1573–1577. 10.1016/j.jpedsurg.2018.01.006 [DOI] [PubMed] [Google Scholar]
- Amato K. R., Yeoman C. J., Kent A., Righini N., Carbonero F., Estrada A., et al. (2013). Habitat degradation impacts black howler monkey (Alouatta pigra) gastrointestinal microbiomes. ISME J. 7 1344–1353. 10.1038/ismej.2013.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Arboleya S., Sánchez B., Milani C., Duranti S., Solís G., Fernández N., et al. (2015). Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. J. Pediatr. 166 538–544. 10.1016/j.jpeds.2014.09.041 [DOI] [PubMed] [Google Scholar]
- Brehin C., Dubois D., Dicky O., Breinig S., Oswald E., Serino M. (2020). Evolution of Gut Microbiome and Metabolome in Suspected Necrotizing Enterocolitis: A Case-Control Study. J. Clin. Med. 9:2278. 10.3390/jcm9072278 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Call L., Stoll B., Oosterloo B., Ajami N., Sheikh F., Wittke A., et al. (2018). Metabolomic signatures distinguish the impact of formula carbohydrates on disease outcome in a preterm piglet model of NEC. Microbiome 6:111. 10.1186/s40168-018-0498-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Claud E. C., Walker W. A. (2001). Hypothesis: Inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J. 15 1398–1403. [DOI] [PubMed] [Google Scholar]
- de la Cochetiere M.-F., Piloquet H., des Robert C., Darmaun D., Galmiche J.-P., Roze J.-C. (2004). Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: The putative role of Clostridium. Pediatr. Res. 56 366–370. [DOI] [PubMed] [Google Scholar]
- den Besten G., van Eunen K., Groen A. K., Venema K., Reijngoud D.-J., Bakker B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54 2325–2340. 10.1194/jlr.R036012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dobbler P. T., Procianoy R. S., Mai V., Silveira R. C., Corso A. L., Rojas B. S., et al. (2017). Low Microbial Diversity and Abnormal Microbial Succession Is Associated with Necrotizing Enterocolitis in Preterm Infants. Front. Microbiol. 8:2243. 10.3389/fmicb.2017.02243 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Foglia E. E., Carper B., Gantz M., DeMauro S. B., Lakshminrusimha S., Walsh M., et al. (2019). Association between Policy Changes for Oxygen Saturation Alarm Settings and Neonatal Morbidity and Mortality in Infants Born Very Preterm. J. Pediatr. 209 17–22.e2. 10.1016/j.jpeds.2019.01.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Frost B. L., Modi B. P., Jaksic T., Caplan M. S. (2017). New Medical and Surgical Insights Into Neonatal Necrotizing Enterocolitis: A Review. JAMA Pediatr. 171 83–88. 10.1001/jamapediatrics.2016.2708 [DOI] [PubMed] [Google Scholar]
- Ghonimy A., Zhang D. M., Farouk M. H., Wang Q. (2018). The Impact of Carnitine on Dietary Fiber and Gut Bacteria Metabolism and Their Mutual Interaction in Monogastrics. Int. J. Mol. Sci. 19:1008. 10.3390/ijms19041008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldstein G. P., Sylvester K. G. (2019). Biomarker Discovery and Utility in Necrotizing Enterocolitis. Clin. Perinatol. 46 1–17. 10.1016/j.clp.2018.10.001 [DOI] [PubMed] [Google Scholar]
- Gonçalves P., Araújo J. R., Di Santo J. P. (2018). A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. Inflamm. Bowel Dis. 24 558–572. 10.1093/ibd/izx029 [DOI] [PubMed] [Google Scholar]
- Huang T., Shi H., Xu Y., Ji L. (2021). The gut microbiota metabolite propionate ameliorates intestinal epithelial barrier dysfunction-mediated Parkinson’s disease via the AKT signaling pathway. Neuroreport 32 244–251. 10.1097/WNR.0000000000001585 [DOI] [PubMed] [Google Scholar]
- Huo R., Liu H., Chen J., Sheng H., Miao L. (2021). Serum HMGB1 level is correlated with serum I-FABP level in neonatal patients with necrotizing enterocolitis. BMC Pediatr. 21:355. 10.1186/s12887-021-02818-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayama H., Okumura R., Takeda K. (2020). Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annu. Rev. Immunol. 38 23–48. 10.1146/annurev-immunol-070119-115104 [DOI] [PubMed] [Google Scholar]
- Kliegman R. M., Walsh M. C. (1987). Neonatal necrotizing enterocolitis: Pathogenesis, classification, and spectrum of illness. Curr. Probl. Pediatr. 17 213–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koh A., De Vadder F., Kovatcheva-Datchary P., Bäckhed F. (2016). From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 165 1332–1345. 10.1016/j.cell.2016.05.041 [DOI] [PubMed] [Google Scholar]
- La Rosa P. S., Warner B. B., Zhou Y., Weinstock G. M., Sodergren E., Hall-Moore C. M., et al. (2014). Patterned progression of bacterial populations in the premature infant gut. Proc. Natl. Acad. Sci. U.S.A. 111 12522–12527. 10.1073/pnas.1409497111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee J. K.-F., Hern Tan L. T., Ramadas A., Ab Mutalib N.-S., Lee L.-H. (2020). Exploring the Role of Gut Bacteria in Health and Disease in Preterm Neonates. Int. J. Environ. Res. Public Health 17:6963. 10.3390/ijerph17196963 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li M., Hu F.-C., Qiao F., Du Z.-Y., Zhang M.-L. (2020). Sodium acetate alleviated high-carbohydrate induced intestinal inflammation by suppressing MAPK and NF-κB signaling pathways in Nile tilapia (Oreochromis niloticus). Fish Shellfish Immunol. 98 758–765. 10.1016/j.fsi.2019.11.024 [DOI] [PubMed] [Google Scholar]
- Li Y., Jia C., Lin X., Lin L., Li L., Fan X., et al. (2021). The Diversity of the Intestinal Flora Disturbed After Feeding Intolerance Recovery in Preterm Twins. Front. Pediatr. 9:648979. 10.3389/fped.2021.648979 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu X.-C., Sun Q., Ji Y.-C., Fu L.-Z., Wang Z.-L., He Y., et al. (2022). Differences in the Gut Microbiota Composition and Metabolites Associated With Feeding Intolerance in VLBW Infants With a Gestational Age of = 30 Weeks: A Pilot Study. Front. Cell. Infect. Microbiol. 12:726322. 10.3389/fcimb.2022.726322 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lynch S. V., Pedersen O. (2016). The Human Intestinal Microbiome in Health and Disease. N. Engl. J. Med. 375 2369–2379. [DOI] [PubMed] [Google Scholar]
- Macia L., Tan J., Vieira A. T., Leach K., Stanley D., Luong S., et al. (2015). Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6:6734. 10.1038/ncomms7734 [DOI] [PubMed] [Google Scholar]
- Mai V., Young C. M., Ukhanova M., Wang X., Sun Y., Casella G., et al. (2011). Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One 6:e20647. 10.1371/journal.pone.0020647 [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCarville J. L., Chen G. Y., Cuevas V. D., Troha K., Ayres J. S. (2020). Microbiota Metabolites in Health and Disease. Annu. Rev. Immunol. 38 147–170. 10.1146/annurev-immunol-071219-125715 [DOI] [PubMed] [Google Scholar]
- McNabney S. M., Henagan T. M. (2017). Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients 9:1348. 10.3390/nu9121348 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meister A. L., Doheny K. K., Travagli R. A. (2020). Necrotizing enterocolitis: It’s not all in the gut. Exp. Biol. Med. 245 85–95. 10.1177/1535370219891971 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu J., Pammi M. (2018). Necrotizing enterocolitis: The intestinal microbiome, metabolome and inflammatory mediators. Semin. Fetal Neonatal Med. 23 400–405. 10.1016/j.siny.2018.08.001 [DOI] [PubMed] [Google Scholar]
- Neu J., Walker W. A. (2011). Necrotizing enterocolitis. N. Engl. J. Med. 364 255–264. 10.1056/NEJMra1005408 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Niño D. F., Sodhi C. P., Hackam D. J. (2016). Necrotizing enterocolitis: New insights into pathogenesis and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 13 590–600. 10.1038/nrgastro.2016.119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olm M. R., Bhattacharya N., Crits-Christoph A., Firek B. A., Baker R., Song Y. S., et al. (2019). Necrotizing enterocolitis is preceded by increased gut bacterial replication, and fimbriae-encoding bacteria. Sci. Adv. 5:eaax5727. 10.1126/sciadv.aax5727 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Onrust L., Van Driessche K., Ducatelle R., Schwarzer K., Haesebrouck F., Van Immerseel F. (2018). Valeric acid glyceride esters in feed promote broiler performance and reduce the incidence of necrotic enteritis. Poult. Sci. 97 2303–2311. 10.3382/ps/pey085 [DOI] [PubMed] [Google Scholar]
- Pace F., Rudolph S. E., Chen Y., Bao B., Kaplan D. L., Watnick P. I. (2021). The Short-Chain Fatty Acids Propionate and Butyrate Augment Adherent-Invasive Escherichia coli Virulence but Repress Inflammation in a Human Intestinal Enteroid Model of Infection. Microbiol. Spectr. 9:e0136921. 10.1128/Spectrum.01369-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pammi M., Cope J., Tarr P. I., Warner B. B., Morrow A. L., Mai V., et al. (2017). Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: A systematic review and meta-analysis. Microbiome 5:31. 10.1186/s40168-017-0248-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schnabl K.-L., Van Aerde J.-E., Thomson A.-B., Clandinin M.-T. (2008). Necrotizing enterocolitis: A multifactorial disease with no cure. World J. Gastroenterol. 14 2142–2161. 10.3748/wjg.14.2142 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Soldavini J., Kaunitz J. D. (2013). Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig. Dis. Sci. 58 2756–2766. 10.1007/s10620-013-2744-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sun Q., Ji Y.-C., Wang Z.-L., She X., He Y., Ai Q., et al. (2021). Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis. Mediators Inflamm. 2021:6259381. 10.1155/2021/6259381 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tarracchini C., Milani C., Longhi G., Fontana F., Mancabelli L., Pintus R., et al. (2021). Unraveling the Microbiome of Necrotizing Enterocolitis: Insights in Novel Microbial and Metabolomic Biomarkers. Microbiol. Spectr. 9:e0117621. 10.1128/Spectrum.01176-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waligora-Dupriet A.-J., Dugay A., Auzeil N., Huerre M., Butel M.-J. (2005). Evidence for clostridial implication in necrotizing enterocolitis through bacterial fermentation in a gnotobiotic quail model. Pediatr. Res. 58 629–635. 10.1203/01.PDR.0000180538.13142.84 [DOI] [PubMed] [Google Scholar]
- Willers M., Ulas T., Völlger L., Vogl T., Heinemann A. S., Pirr S., et al. (2020). S100A8 and S100A9 Are Important for Postnatal Development of Gut Microbiota and Immune System in Mice and Infants. Gastroenterology 159 2130–2145.e5. 10.1053/j.gastro.2020.08.019 [DOI] [PubMed] [Google Scholar]
- Zhu W., Gregory J. C., Org E., Buffa J. A., Gupta N., Wang Z., et al. (2016). Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 165 111–124. 10.1016/j.cell.2016.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets for this study can be found in the NCBI (BioProject ID: PRJNA832593 http://www.ncbi.nlm.nih.gov/bioproject/832593) and obtained from the corresponding author.